Predict your next investment

Anchor Therapeutics company logo
HEALTHCARE | Drug Delivery
anchortx.com

See what CB Insights has to offer

Stage

Series C | Alive

Total Raised

$10M

About Anchor Therapeutics

Anchor Therapeutics is developing first-in-class pepducin drug candidates, novel molecules that can selectively target G protein coupled receptors (GPCRs) to allosterically modulate GPCR signaling.

Anchor Therapeutics Headquarter Location

67 Rogers Street

Cambridge, Massachusetts, 02142,

United States

508-545-2590

Latest Anchor Therapeutics News

Robert Kamen, Ph.D., Joins ShangBay Capital as a Senior Advisor

Nov 3, 2021

Robert Kamen, Ph.D., Joins ShangBay Capital as a Senior Advisor PALO ALTO, Calif., November 2, 2021-- ShangBay Capital, a venture capital firm focused on investing in early-stage healthcare companies, today announced that Robert Kamen, Ph.D., has joined its advisory team as a Senior Advisor. The venture capital firm is one of the most prolific investors in medtech. Dr. Kamen will provide tremendous value in the biotech and biopharma investment fields for potential new companies. ShangBay Capital’s team has a proven track record of identifying, financing, and building various healthcare companies over the last several years. The team brings deep operational experience from more than 100 years of combined industry experience to help entrepreneurs build lasting companies. “Bob will bring significant value from his more than 35 years of experience of launching and operating successful biotech and pharmaceutical companies,” said William Dai, Founding Managing Partner. “His in-depth experience will help ShangBay continue to build a great portfolio of disruptive biotechnologies to improve patient outcome.” Dr. Kamen is also a venture partner at Third Rock Ventures. Prior to that, he served as an executive-in-residence at Oxford Bioscience Partners. Dr. Kamen’s career began as Senior VP Scientific Affairs at Genetics Institute, Inc., a pioneering biopharmaceutical firm that was acquired by Wyeth. He previously served as president of Abbott Bioresearch Center, where he oversaw the discovery and production of Humira, the first fully human antibody to achieve marketing approval in the U.S. and Europe and was a member of the Abbott Pharmaceuticals Executive Management Committee. He also was the president of the BASF Bioresearch Corp. until it was acquired by Abbott Laboratories in 2001. Dr. Kamen is a co-founder of BioAssets Development Corporation, a biotherapeutics company focusing on spinal diseases, that was acquired by Cephalon. Dr. Kamen serves as a director of Jounce Therapeutics, Harbour Biomed, and EpimAb Biotherapeutics. He previously served as a director at Neon Therapeutics, Harbour Antibodies, Lycera, Opsonic Therapeutics, and Anchor Therapeutics and was a member of the GlaxoSmithKline Biopharma Investment Board. Dr. Kamen received his undergraduate degree in biophysics from Amherst College (summa cum laude) and his Ph.D. in biochemistry and molecular biology from Harvard University. About ShangBay Capital Founded in 2015, ShangBay Capital is a Silicon Valley-based venture capital company that brings investors access to best-in-class investments in U.S. medical device technologies, biotechnology, biopharmaceutical, and digital health sectors through early-stage venture equity participation. Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Anchor Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Anchor Therapeutics is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Anchor Therapeutics Patents

Anchor Therapeutics has filed 4 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/25/2011

10/13/2015

G protein coupled receptors, Clusters of differentiation, Autoimmune diseases, Olfactory receptors, Monoclonal antibodies

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

2/25/2011

00/00/0000

00/00/0000

00/00/0000

Grant Date

10/13/2015

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

G protein coupled receptors, Clusters of differentiation, Autoimmune diseases, Olfactory receptors, Monoclonal antibodies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Anchor Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Anchor Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.